United Therapeutics generated $3.2B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $1.3B with a 40.61% net margin. Gross margin stands at 86.58% and operating margin at 45.29%. Diluted EPS is $27.05, which grew 0.1% year-over-year. Based on the Q1 2026 filing.